Scientific work

Doç. Dr. Özgen Ahmet Yıldırım

38 publications. The source of the information is stated next to each publication.

Back to profile

  1. Clinicopathological Predictors of Pathological Complete Response in HER2-Positive Breast Cancer Treated with Pertuzumab-Based Neoadjuvant Therapy: A Multicenter Real-World Study

    Medicina, 2026

    DOI 10.3390/medicina62040763 PMID 42075632 Open-access full textSource: ORCID

  2. Level II (IIA/IIB) Lymph Node Evaluation in Head and Neck Cancer: A Retrospective Cohort Study from a Non-Endemic Region

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15031068 PMID 41682748 Open-access full textSource: ORCID

  3. Exploring the impacts of docetaxel and paclitaxel based neoadjuvant therapies on early postoperative complications in HER2-positive breast cancer patients

    World journal of surgical oncology, 2026

    DOI 10.1186/s12957-026-04434-z PMID 42192428 Open-access full textSource: Europe PMC

  4. Claudin 18.2 Positivity Thresholds and Candidate Populations for Targeted Therapy in Pancreatic Ductal Adenocarcinoma: A Real-World Retrospective Cohort

    Cancers, 2026

    DOI 10.3390/cancers18172827 PMID 42738347 Open-access full textSource: OpenAlex

  5. Structural Acceleration in Sepsis-Associated Cancer Mortality in an Aging Population: A Nationwide Study in the United States, 1999–2020

    SSRN Electronic Journal, 2026

    DOI 10.2139/ssrn.6201853 Open-access full textSource: OpenAlex

  6. Hepatocellular carcinoma in Turkey: A nationwide health system database analysis of clinical patterns and survival

    Cancer Epidemiology, 2026

    DOI 10.1016/j.canep.2026.103255 PMID 42887435 Source: ORCID

  7. The Role of Dominant Lesion Site and SUVmax in the Depth of PSA Response in Metastatic Hormone-Sensitive Prostate Cancer

    Biomedicines, 2026

    DOI 10.3390/biomedicines14102160 PMID 42939968 Open-access full textSource: ORCID

  8. Proton Pump Inhibitor Use and Survival Outcomes in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Immunotherapy: A Real-World Study

    Medicina, 2026

    DOI 10.3390/medicina62071413 PMID 42512955 Open-access full textSource: ORCID

  9. Impact of COVID-19 Vaccine Type on the Efficacy and Safety of Nivolumab in Patients With Metastatic Non-small-cell Lung Cancer: A Multicenter Study

    In Vivo, 2026

    DOI 10.21873/invivo.14401 PMID 42379805 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  10. Hospitalized oncology patients with diarrhea: Clinical outcomes and prognostic factors.

    Journal of Clinical Oncology, 2026

    DOI 10.1200/jco.2026.44.16_suppl.11136 Source: OpenAlex

  11. Pathologic response in relation to total neoadjuvant therapy sequence, completion, and extra consolidation chemotherapy in locally advanced rectal cancer.

    Journal of Clinical Oncology, 2026

    DOI 10.1200/jco.2026.44.16_suppl.e15648 Open-access full textSource: OpenAlex

  12. Monoallelic germline RAD51C, RAD51D, and BRIP1 variants in hereditary cancer testing: Variant spectrum and clinical counselling implications

    Mutation research. Fundamental and molecular mechanisms of mutagenesis, 2026

    DOI 10.1016/j.mrfmmm.2026.111941 PMID 42322921 Source: OpenAlex

  13. Wearable-derived postdischarge mobility as a digital biomarker for 90-day readmission and mortality in metastatic cancer

    Supportive Care in Cancer, 2026

    DOI 10.1007/s00520-026-11216-6 PMID 42726154 Source: OpenAlex

  14. Real-world treatment patterns and prognostic indicators in upper tract urothelial carcinoma: A Turkish Oncology Group (TOG) study

    European Urology Open Science, 2025

    DOI 10.1016/s2666-1683(25)01751-3 Open-access full textSource: OpenAlex

  15. CALLY index as an independent predictor of pathological complete response in HER2-positive breast cancer receiving neoadjuvant therapy

    Clinical and Translational Oncology, 2025

    DOI 10.1007/s12094-025-04077-8 PMID 41091451 8 citations (Europe PMC) Source: ORCID

  16. The Accuracy and Sensitivity of Delta Neutrophil Index in Malignancy: Diagnostic Study of Different Types

    Diagnostics, 2025

    DOI 10.3390/diagnostics15243187 PMID 41464189 Open-access full textSource: OpenAlex

  17. A CASE REPORT OF NON-SMALL CELL LUNG CANCER PRESENTED WITH METASTATIC SUBCUTANEOUS NODULE ON BREAST SKIN AND COEXISTING SECOND PRIMARY INVASIVE BREAST CANCER WITHIN THE SAME BREAST

    2024

    DOI 10.22541/au.172444784.41256739/v1 Open-access full textSource: OpenAlex

  18. Clinicopathological Features and First-Line Treatment Outcomes of Geriatric Patients With Extensive-Stage Small Cell Lung Cancer: A Multicenter Study

    Cureus, 2023

    DOI 10.7759/cureus.35710 PMID 36875256 2 citations (OpenAlex) Open-access full textSource: OpenAlex

  19. Lorlatinib-Related Vision Loss: Two Cases of Non-Small Cell Lung Cancer with Blindness

    Journal of Oncological Sciences, 2023

    DOI 10.37047/jos.2022-92714 3 citations (OpenAlex) Open-access full textSource: OpenAlex

  20. Onkolojide Moleküler Hedefli Tedaviler

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1478 Open-access full textSource: OpenAlex

  21. Toraks Tümörleri

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1073 Open-access full textSource: OpenAlex

  22. Evaluation of caregiver burden of cancer patients and impact of this burden on caregiver's quality of life

    Journal of Health Sciences and Medicine, 2022

    DOI 10.32322/jhsm.1025215 3 citations (OpenAlex) Open-access full textSource: ORCID

  23. Pancreatic cancer treatment after FOLFIRINOX: prognostic importance of chemotherapy dose intensity and albumin/globulin ratio in second line

    Journal of Health Sciences and Medicine, 2022

    DOI 10.32322/jhsm.1011658 Open-access full textSource: ORCID

  24. Evaluation of cancer patients receiving concurrent chemotherapy and antituberculosis treatment: Review and case series of a single-center experience

    Journal of Surgery and Medicine, 2022

    DOI 10.28982/josam.1015461 2 citations (OpenAlex) Open-access full textSource: OpenAlex

  25. Medical Oncology or Surgical Oncology: Which Branch Should Be Started in Esophageal Cancer Diagnostic Evaluation?

    Cureus, 2022

    DOI 10.7759/cureus.22286 PMID 35350502 2 citations (OpenAlex) Open-access full textSource: OpenAlex

  26. Roles of metabolic tumor volume and total lesion glycolysis on 18F-FDG PET/CT, CA19-9 levels, and complete blood count parameters in predicting survival in patients with unresectable or metastatic pancreatic cancer.

    PubMed, 2022

    PMID 35166229 1 citation (OpenAlex) Source: OpenAlex

  27. Prognostic Markers in the Treatment of Abiraterone Acetate + Prednisolone and Enzalutamide in Castration-Resistant Metastatic Prostate Cancer

    Eurasian Journal of Medical Investigation, 2022

    DOI 10.14744/ejmi.2022.22832 Source: OpenAlex

  28. Gastrointestinal Sistem Tümörleri-2

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1212 Open-access full textSource: OpenAlex

  29. The role of inflammatory parameters in predicting disease recurrence in patients with stage IIA colon cancer with no high-risk features

    Postgraduate Medicine, 2021

    DOI 10.1080/00325481.2021.1934493 PMID 34030576 2 citations (Europe PMC) Source: ORCID

  30. Nivolumab-Related Dry Mouth and Dry Eye: Cross-Sectional Study

    Cancer Investigation, 2021

    DOI 10.1080/07357907.2021.1971241 PMID 34415812 4 citations (Europe PMC) Open-access full textSource: ORCID

  31. Depression and anxiety in cancer patients before and during the SARS-CoV-2 pandemic: association with treatment delays

    Quality of Life Research, 2021

    DOI 10.1007/s11136-021-02795-4 PMID 33635508 38 citations (Europe PMC) Open-access full textSource: ORCID

  32. Evaluation of caregiver burden, and quality of life in metastatic prostate cancer patients and caregivers; Effects of clinical and socioeconomic factors

    2021

    DOI 10.21203/rs.3.rs-359207/v1 Open-access full textSource: ORCID

  33. 68Ga-FAPI-04 PET/CT, a new step in breast cancer imaging: a comparative pilot study with the 18F-FDG PET/CT

    Annals of Nuclear Medicine, 2021

    DOI 10.1007/s12149-021-01616-5 PMID 33934311 162 citations (OpenAlex) Source: OpenAlex

  34. Correlations between whole body volumetric parameters of 68Ga-PSMA PET/CT and biochemical-histopathological parameters in castration-naive and resistant prostate cancer patients

    Annals of Nuclear Medicine, 2021

    DOI 10.1007/s12149-021-01594-8 PMID 33586097 8 citations (OpenAlex) Source: OpenAlex

  35. Role of 68Ga-PSMA PET/CT parameters in treatment evaluation and survival prediction in prostate cancer patients compared with biochemical response assessment.

    PubMed, 2021

    DOI 10.1967/s002449912303 PMID 33866336 6 citations (OpenAlex) Source: OpenAlex

  36. Evaluation of caregiver burden and quality of life in metastatic prostate cancer patients; Effects of clinical and socioeconomic factors

    Dicle Medical Journal / Dicle Tip Dergisi, 2021

    DOI 10.5798/dicletip.1037634 2 citations (OpenAlex) Open-access full textSource: OpenAlex

  37. Multimodality Treatment For Peritoneal Mesothelioma: A Single Center Experience

    Acta Oncologica Turcica, 2020

    DOI 10.5505/aot.2020.71931 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  38. Short term real world safety data of pertuzumab use in HER2 targeted treatment of metastatic breast cancer

    Journal of Oncological Sciences, 2018

    DOI 10.1016/j.jons.2017.12.002 2 citations (OpenAlex) Open-access full textSource: ORCID